Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab does not improve outcomes in advanced UC

Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer

Ultra-sensitive ctDNA detects residual disease and predicts recurrence early in RCC

Cabozantinib plus nivolumab and ipilimumab improves response in low GDS mRCC while high GDS predicts worse survival

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer

AMVAC plus nivolumab in muscle-invasive bladder cancer preserves bladder and predicts metastatic control with ctDNA

Real-world cardiovascular risks with novel hormonal therapies in advanced prostate cancer

Circulating tumour DNA shows high accuracy for monitoring testicular cancer across all stages

Cabozantinib plus nivolumab and ipilimumab shows promising brain metastasis control in advanced kidney cancer

Belzutifan plus palbociclib shows modest activity with manageable safety in heavily pretreated kidney cancer

Circulating tumour DNA dynamics predict outcomes with pembrolizumab in advanced kidney cancer

HIF-2α inhibitor Cas shows durable responses and biomarker-linked benefit in metastatic kidney cancer